Cipla, a fifth largest pharmaceutical company in India with net sales of Rs.13,300 crore plus, has received four observations for its three manufacturing facilities at Goa. These observations were primarily procedural in nature and the company has already responded to these observations.
Despite US FDA observations, Cipla scrip opened today at Rs.582.45 on BSE as compared to its previous days close of Rs.580.25. Cipla touched to yearly high level at Rs.704.75 on October 29, 2015 and lowest at Rs.458.25 on May 25, 2016.